1995 issue 1


Volume 4, issue 1

Choroby naczyniowe

Antiplatelet medication in secondary prevention of brain stroke

Anna Członkowska1
1. Kliniki Chorób Naczyniowych Układu Nerwowego IPiN w Warszawie
Postępy Psychiatrii i Neurologii, 1995, 4, 69-75
Keywords: brain strokes, prevention, Aspirin, Ticlopidine


After an ischaemic brain stroke or transient ischaemic attack (TIA) of the brain the risk of another stroke within the following 3 years ranges from 20 to 25%. Meta-analysis of data from many studies indicates that the risk of vascular incidents may be reduced in secondary prevention by 25 to 30 % with medication decreasing blood platelets activity. Therapeutic efficacy in the secondary prevention of stroke is confirmed only for Aspirin and Ticlopidine. Aspirin is the most popular drug, but in the case of intolerance to Aspirin or recurrence of vascular incidents in the course of Aspirin treatment, the drug of choice is Ticlopidine.

Address for correspondence:
Prof Anna Członkowska,
Klinika Chorób Naczyniowych Układu Nerwowego IPiN,
AI.Sobieskiego 1/9,
02-957 Warszawa